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The relationship between smoking and pulmonary ﬁbrosis is under debate and intense investigation. The aim of this paper is to
review the existing literature and identify further areas of research interest. Recently the negative inﬂuence of cigarette smokingon
IPFoutcomewashighlighted,asnon-smokersexhibit abetter survivalthanex-smokersandcombinedcurrent- andex-smokers.In
patients with non-speciﬁc interstitial pneumonia (NSIP), a high prevalence of emphysema was recently demonstrated, providing
an indirect support for a smoking pathogenetic hypothesis in NSIP. The coexistence of pulmonary ﬁbrosis and emphysema
has been extensively described in a syndrome termed combined pulmonary ﬁbrosis and emphysema (CPFE). Connective tissue
disorders (CTDs)are agroup ofautoimmunediseases which aﬀectthelung,asoneofthemostcommonandseveremanifestations.
However, the relationship between smoking and autoimmune disorders is still conﬂicting. Rheumatoid arthritis results from
the interaction between genetic and environmental factors, while the best established environmental factor is tobacco smoking.
Smoking has also a negative impact on the response of the RA patients to treatment. The aforementioned smoking-related
implications give rise to further research questions and certainly provide one more important reason for physicians to advocate
smokingcessation and smoke-free environment.
1.Introduction
Smoking is one of the most prevalent and addictive habits,
aﬀecting billions of people and inﬂuencing their behaviour.
The health risks and eﬀects of tobacco smoking are well
known, and their span aﬀectsmultiple systems of the human
body. The direct pathogenetic relationship between cigarette
smoking and certain respiratory diseases such as emphy-
sema, chronic obstructive pulmonary disease (COPD), and
lung cancer is well documented [1]. Regarding interstitial
lung damage there is strong evidence providing links with
cigarettesmoking. Smokinghasbeenidentiﬁedasacausative
agent in some diﬀuse parenchymal diseases like respiratory
bronchiolitis-interstitial lung disease (RB-ILD) and desqua-
mative interstitial pneumonia (DIP). These diseases have
a fairly good prognosis following smoking cessation and
treatment [2]. However the relationship between smoking
and IPF, the idiopathic interstitial pneumonia with the worst
overall prognosis and survival, is under debate, intense
research, and investigation. The aim of this paper is to review
the existing literature and identify further areas of research
interest.
2.IdiopathicInterstitialPneumonias
Recently Katzenstein et al. reported the presence of frequent
and often severe ﬁbrosis in cigarette smokers undergoing lo-
bectomy surgery for lung cancer with no clinical evidence of
interstitial lung disease [3]. This type of ﬁbrosis is not classi-
ﬁable by the current criteria for interstitial pneumonias but
hasdistincthistologicfeaturesandwastermedbytheauthors
as smoking-related interstitial ﬁbrosis (SRIF). SRIF lacks
the distinct characteristics of usual interstitial pneumonia
(UIP) like honeycomb changes and ﬁbroblastic foci and
also lacks signiﬁcant inﬂammation that characterises NSIP.
What is common in SRIF alongside ﬁbrosis is the presence
of emphysema, highlighting the smoking-related origin of2 Pulmonary Medicine
this ﬁbrotic phenotype [3]. Complementing the search for
smoking-related ﬁbrosis in pathology sections, high-res-
olution CT (HRCT) has been a useful tool in the study of
smoking-related interstitial pneumonias. In a retrospective
HRCT study, Marten et al. compared the prevalence and
extent of emphysema in smokers with NSIP versus smokers
with clinical disease (chronic obstructive pulmonary disease
(COPD)and “healthy”smokers [4].The resultsrevealedem-
physema in a striking majority of NSIP cases (77.8%) and
COPD cases (73.5%) but not so in the “healthy” smokers
(17.5%). The high prevalence of emphysema in the NSIP
patients, which did not diﬀer from the COPD controls,
provided, according to the authors, an indirect support for
a smoking pathogenetic hypothesis in some NSIP patients
[4]. The coexistence of pulmonary ﬁbrosis and emphysema
was extensively described for the ﬁrst time in 2005 by
Cottin et al. in a syndrome termed combined pulmonary
ﬁbrosis and emphysema (CPFE) [5]. Patients with CPFE are
mostly older, male, current, orex-smokers, exhibiting HRCT
ﬁbrotic changes such as honeycombing, reticulation and
traction bronchiectasis plus emphysema mostly paraseptal.
CPFE patients exhibit distinct, mixed patterns of pulmonary
function tests compared to IPF and COPD patients; lung
volumes remain near normal due to emphysema and hy-
perinﬂation, whereas carbon monoxide diﬀusing capacity
is overly decreased and exercise hypoxemia is present. Also
the prevalence of pulmonary hypertension (PAH) was very
high among CPFE patients (44%) compared to both IPF and
COPD patients. The presence of PAH in patients with both
pulmonary ﬁbrosis and emphysema is associated with more
severe disease course and poor survival, as was also reported
by Mej´ ıa and colleagues in 2009 [6]. Emphysema and ﬁ-
brosis in this syndrome are radiographically described to
be concurrent and possible genetic or environmental factors
that interact with smoking as a trigger are explored [5, 6]. In
an experimental mouse model by Lundblad et al. the overex-
pression oftumor necrosis factor-(TNF-) αresulted in major
changes in the lungs of the animals, including both ﬁbrosis
and emphysematous-like airspace dilatations, thus resem-
bling a possible experimental model of CPFE [7].
Although cigarette smoking is believed to be a risk factor
for the development of IPF and the disease is known to
occurmore frequentlyinsmokers[5, 8],therehasbeensome
debate regarding possible pathogenetic implications and the
eﬀect smoking has on the outcome of the disease. A better
survival in current smokers at time of diagnosis with IPF
as compared to ex-smokers was reported in 2001 by King
Jr. et al. [9]. Possible explanations for the longer survival
in patients with IPF who are smoking cigarettes at the time
of their initial presentation were that possibly smokers seek
attention earlier because of smoking-related symptoms, thus
being identiﬁed as IPF in a mild stage of the disease. In
contrast other smokers attribute their overall symptoms to
smoking and postpone medical care until their disease has
progressed enough to dictate smoking cessation due to dys-
pnea. A subsequent study by Antoniou and colleagues also
addressed the issue of smoking eﬀect in IPF survival [10].
Smoking-related lung damage and, especially, concurrent
emphysemahaveamajorconfounding eﬀectinIPF,resulting
in preservation of lung volumes and a steep decrease in
gas transfer. Moreover, in severe IPF cases, emphysematous
regions can be mixed with honeycomb changes—thus the
authors used the composite physiologic index (CPI) [11]
as a severity variable able to take smoking-related damage
independently into account. The authors reported that non-
smokers exhibited a better survival and severity-adjusted
survival than both ex-smokers and the combined group
of current and ex-smokers, thus highlighting the negative
inﬂuence of cigarette smoking on IPF outcome. The better
outcome in the current smokers group when compared
to the ex-smokers was attributed to less severe disease at
presentation, described as a “healthy smoker eﬀect” [10].
Another possible eﬀect of smoking in IPF development,
outcome,andresponsetotreatmentcouldberelatedwiththe
regulation of inﬂammatory genes. Posttranslational modi-
ﬁcations of histone proteins in chromatin structure play a
centralroleintheepigeneticregulationofgenetranscription.
Histone acetylation and methylation are the two most com-
mon and best characterized modiﬁcations that function
as speciﬁc transcription regulators. In interstitial lung dis-
ease, the high level of oxidative stress may impair histone
deacetylase-(HDAC-) 2 activity, and we know that cigarette
smoke induces acetylation of histone H4 and decreases
HDAC2 activity and expression [12]. Recently, Coward and
colleagues reported that defective histone acetylation is re-
sponsible for the repression of the antiﬁbrotic cyclooxygen-
ase-2 gene in IPF [13] .T h es a m eg r o u pa l s or e p o r t e dt h e
repression ofanotherantiﬁbroticgene,thepotentangiostatic
chemokine gamma interferon-(IFN-γ-) inducible protein of
10kDa (IP-10), in lung ﬁbroblasts from patients with IPF,
via histone H3 hypermethylation [14]. More importantly,
treatment of diseased cells with HDAC or G9a inhibitors
similarly reversed the repressive histone deacetylation and
hypermethylation and restored IP-10 expression. These ﬁnd-
ings strongly suggest that epigenetic dysregulation involving
interactions between histone deacetylation and hypermethy-
lation is responsible for targeted repression of IP-10 and
potentially other antiﬁbrotic genes in ﬁbrotic lung disease
and that this is amenable to therapeutic targeting. Further
studies are needed to investigate the relationship between
smoking and HDAC dysregulation in IPF, as well as the dif-
ferences between smokers and non-smokers.
3.ConnectiveTissueDisorders-Associated
InterstitialLungDisease
Tobacco smoking has serious eﬀects on both the innate
and the adaptive immunity. It is associated with multiple
proinﬂammatory eﬀects favouring allergic and autoimmune
reactions and also immune-suppressive eﬀects predisposing
to a lower activity of the immune system against infections.
The relationship between smoking and autoimmune dis-
orders is conﬂicting. Environmental factors and exposures
including infections, vaccines, drugs, and smoking have
been involvedin thecomplex pathogenesisand clinicaldevel-
opment of autoimmune disorders [15]. Connective tissue
disorders (CTDs) are a group of autoimmune diseases whichPulmonary Medicine 3
aﬀect mainly the joints but frequently present also extra-
articular manifestation, with lung involvement being one of
the most common. Most of the anatomic compartments of
the lung can be aﬀected. Interstitial lung disease associated
to CTDs has a prevalence of 15% [16]. Rheumatoid arthritis
(RA) is a disorder that results from the interaction between
genetic and environmental factors. The best established en-
vironmental factor is tobacco smoking whereas the best
established genetic factor is HLA-DRB1 shared epitope (SE).
Longer duration and severity of smoking increase the risk
of RA, which remains high until 10–20 years after smoking
cessation [17, 18]. However, it has been demonstrated that
both smoking and HLA-DRB1 SE are risk factors exclusively
for anticitrulline-positive but not anticitrulline-negative RA
and that thereis an association of HLA-DRSE with citrulline
immunity rather than with RF positivity [19–22]. Recently
another gene-environment association has been demon-
strated. Polymorphisms of peptidyl-arginine deiminase 4
(PADI4), one of the enzymes that catalyze the citrullination
process, highly predispose male smokers to RA, and the
genetic heterogeneity observed in the PADI4 polymorphism
between populations of Asian and European countries may
be partly explained by diﬀerences in smoking prevalences
amongmen[23].Klareskogetal.haveobservedthatsmoking
is associated with citrullination in the lung by determining
the presence of citrullinated proteins in the cells of BAL
ﬂuid of smokers (healthy individuals and patients with
pulmonary inﬂammatory conditions) whereas citrullinated
proteins were absent in the cells of BAL ﬂuid of nonsmokers
[19]. Later, Bongartz et al. have shown that citrullinated
proteins are also present in the lung tissue of patients with
interstitial pneumonia associated with RA (RA-IP) as well
as in patients with idiopathic interstitial pneumonia (IIP),
but high antibodies to citrullinated protein antigen (ACPA)
titers have been observed only in RA-IP and not in IIP. These
ﬁndingssuggestthatcitrullinationcancontributetothelocal
pathologyinACPA-positiveRApatientsandthatthisprocess
isnotRAspeciﬁcbutassociatedwithinﬂammation incertain
patients. Interestingly, they found no association between
citrullination and smoking status [24]. Smoking has also an
impact on the response of the RA patients to treatment. It
has been shown that current smokers with early diagnosed
RA did not have a good response to biologic agents such as
methotrexate and tumornecrosis factor inhibitorscompared
to former or never-smokers [25].
In a very recent study the eﬀect of smoking regarding
the respiratory outcome has been evaluated in a cohort of
smokers (current, ex) and non smokers with systemic scle-
rosis (SSc) [26]. The authors have used the Comprehensive
Smoking Index (CSI) which integrates components such as
smoking intensity, smoking cessation, and time since cessa-
tionintoasingle covariateofsmoking eﬀect.Theyhavedem-
onstrated a strong negative correlation of smoking intensity
and the FEV1/FVC ratio and a trend towards worsening of
DLco. In addition, it was observed that the eﬀect of smoking
on DLco is cumulative and almost permanent since DLco
c o n t i n u e st od e c l i n ef o r1 6y e a r sa f t e rs m o k i n gc e s s a t i o na n d
only at that time it can start recovering although very slowly.
In another study where the impact of smoking in the lung
function test pattern has been evaluated, the authors found
that, while the restrictive pattern is the most common, the
presence of an obstructive element is independent of the
smoking statusandcanbeobservedalsoinnonsmokers[27].
Finally, in another recent study, the presence of combined
pulmonary ﬁbrosis and emphysema (CPFE) has been eval-
uated in the context of CTDs [28]. The authors compared
patients with CTD and CPFE to patients with CTD without
emphysema. Most of the patients of the former group were
smokers (current/ex) and had a greater pack-year smoking
history, higher lung volumes, lower FEV1/FVC ratio and
lower diﬀusing capacity when compared to the patients of
the latter group. The absence of emphysema which is a well-
deﬁned smoking-related damage could explain these dif-
ferences.
4.Conclusions
Inthepast tenyearsthe roleofcigarettesmoking inthe path-
ogenesis, progression and outcome of interstitial lung dis-
orders, both idiopathic, and secondary, has been elucidated.
A number of smoking-related pathogenetic implications are
now being established giving rise to further research ques-
tions. The interaction of smoking and genetic susceptibility
in the pathogenesis of lung ﬁbrosis is multiple and complex.
The issue of smoking aﬀecting the patients’ response to
treatment has to be addressed, in order to provide therapies
tailored to diﬀerent patient groups needs. Furthermore
smoking could be associated independently with serum or
BAL biomarkers providing insight in the outcome of ﬁbrotic
lung diseases. It is important to remember, however, that,
apart from investigating smoking-related pathogenetic path-
ways and other harmful consequences, all physicians have to
advocate smoking cessation and a smoke-free environment.
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